Alnylam to Webcast its R&D Day on Tuesday, December 5, 2006.CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its R&D Day presentation will be webcast live on the "Investors" section of the company's website at www.alnylam.com. Alnylam's management, scientists, and other invited speakers will review the company's research and development programs. The presentations will be delivered on Tuesday, December 5, 2006 from approximately 8:30 a.m. to 11:45 a.m. ET from the Sofitel New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. , or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the "emerging/mid-cap" company recipient of the 2006 James D. Watson James Dewey Watson (born April 6, 1928) is an American molecular biologist, best known as one of the co-discoverers of the structure of DNA. Watson, Francis Crick, and Maurice Wilkins were awarded the 1962 Nobel Prize in Physiology or Medicine "for their discoveries concerning the Helix Award, the biotechnology industry's award for outstanding achievement. For more information, visit www.alnylam.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion